Compare Coursera Inc (COUR) vs CVS Health Corp (CVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs CVS Health Corp — how do they compare? Coursera Inc trades at $5.2 (market cap $1.39B), while CVS Health Corp trades at $86.24 (market cap $112.29B). The key difference: CVS Health Corp is far larger — about 80.8× Coursera Inc's market cap, and CVS Health Corp pays a 3.03% dividend while Coursera Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Coursera Inc for 47 Days and CVS Health Corp for 83 Days on average.
| COUR | CVS | |
|---|---|---|
Market Cap | $1.39B | $112.29B |
Volume | 9,728,980 | 7,763,676 |
Sector | Consumer Staples | Health |
52-Week High | $10.73 | $110.60 |
52-Week Low | $4.64 | $70.08 |
Typical Hold Time | 47 Days | 83 Days |
Enterprise Value | $648.49M | $174.64B |
Dividend Yield | — | 3.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coursera (COUR) trades at $5.235, up 2.45% today, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. Revenue has grown steadily from $524M in 2022 to $758M in 2025, though the company remains unprofitable with a net loss of $51M in 2025. Recent news highlights strong institutional interest, including a 137% surge in call option volume (Defense World, 2026-10-01) and the launch of Project Helix, an AI-native learning platform (Business Wire, 2026-09-09).
The stock offers upside to the $7.40 analyst consensus target but faces risks from persistent losses and integration challenges. Positive cash flow and subscriber growth are key strengths, yet profitability remains elusive. Investors should weigh the 52.94% buy rating against high RSI levels and competitive pressures in the edtech sector.
CVS Health trades at $86.16, down 2.04% for the day, amid a bearish technical signal. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.58 exceeding the $1.85 estimate. Revenue grew to $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst consensus is overwhelmingly positive, with 35 of 41 analysts rating the stock a Buy and a consensus price target of $111.20, implying significant upside. Recent news highlights Aetna's 2027 Medicare plan updates and a quarterly dividend declaration.
The outlook for CVS remains favorable based on fundamental strength and analyst optimism, but risks include reimbursement pressure, regulatory scrutiny, and a high debt load. The stock's current valuation metrics, such as a P/E of 23.17 and P/S of 0.27, appear reasonable relative to historical levels, supporting a constructive view for long-term investors despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →
